Patents by Inventor Patrick Hwu

Patrick Hwu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240009240
    Abstract: This disclosure provides for engineered T cell Receptors (TCRs), cells comprising the TCRs, and methods of making and using the TCRs. The current disclosure relates to TCRs that specifically recognize EGFR neoantigens comprising L858R mutations and restricted to HLA class I A11 allotype. Accordingly, aspects of the disclosure relate to a polypeptide comprising an antigen binding variable region comprising the amino acid sequence of a CDR3 of the disclosure or an amino acid sequence with at least 80% sequence identity to a CDR3 of the disclosure.
    Type: Application
    Filed: November 4, 2021
    Publication date: January 11, 2024
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Patrick HWU, Fenge LI, Gregory LIZEE
  • Publication number: 20240009241
    Abstract: This disclosure provides for engineered T cell Receptors (TCRs), cells comprising the TCRs, and methods of making and using the TCRs. The current disclosure relates to TCRs that specifically recognize EGFR neoantigens comprising L858R mutations and restricted to HLA class I A31 and A33 allotypes. Accordingly, aspects of the disclosure relate to a polypeptide comprising an antigen binding variable region comprising the amino acid sequence of a CDR3 of the disclosure or an amino acid sequence with at least 80% sequence identity to a CDR3 of the disclosure.
    Type: Application
    Filed: November 4, 2021
    Publication date: January 11, 2024
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Patrick HWU, Cassian YEE, Geogory LIZEE
  • Publication number: 20230285558
    Abstract: Embodiments of the disclosure encompass methods and compositions related to cell therapy treatment, including for cancer. In specific embodiments, the disclosure concerns adoptive cell therapy cancer treatment in which tumor-1 infiltrating lymphocytes and/or engineered T cells are modified to increase their efficacy as a cancer treatment. In specific cases, the cells are engineered for knock out of one or more genes, such as Signaling Threshold Regulating Transmembrane Adaptor 1 (SIT1), Bone Marrow Stromal Cell Antigen 2 (BST2), and/or programmed cell death protein 1 (PD-1).
    Type: Application
    Filed: July 23, 2021
    Publication date: September 14, 2023
    Applicant: Board of Regents, The University of Texas System
    Inventors: Patrick HWU, Barbara M. NASSIF RAUSSEO
  • Patent number: 11673966
    Abstract: The present invention discloses a mouse-human chimeric antibody preferably recognizes the MUC1 glycopeptide epitope RPAPGS(GalNAc)TAPPAHG (SEQ ID NO.: 34) on the surface of cancer cells, and the encoding sequences, wherein the monoclonal antibody having a light chain and a heavy chain. Moreover, the present invention provides humanized light and heavy chains, and the encoding sequences. The results of paired expression show that humanized antibodies also recognize the MUC1 glycopeptide epitope RPAPGS(GalNAc)TAPPAHG (SEQ ID NO.: 34) on the surface of cancer cells, and show the same specificity as the parental antibody.
    Type: Grant
    Filed: January 18, 2017
    Date of Patent: June 13, 2023
    Assignees: NanoCruise Pharmaceutical Ltd., Board of Regents of The University of Texas System
    Inventors: Dapeng Zhou, Patrick Hwu
  • Publication number: 20230106973
    Abstract: Provided herein are methods for the activation and expansion of genetically-modified Tcells, such as tumor infiltrating lymphocytes. In some cases, cells of the embodiments can be used for the therapeutic treatment of human diseases, such as cancer.
    Type: Application
    Filed: February 16, 2021
    Publication date: April 6, 2023
    Applicant: Board of Regents, The University of Texas System
    Inventors: Marie-Andrée FORGET, Chantale BERNATCHEZ, Cara HAYMAKER, Michael A. CURRAN, Patrick HWU, Cassian YEE
  • Patent number: 11594135
    Abstract: Provided herein are methods and compositions for treating cancer in an individual comprising administering to the individual an effective amount of at least one immune checkpoint inhibitor and a chimeric CD 154 polypeptide. Also provided herein are methods of enhanced immune function.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: February 28, 2023
    Assignees: MEMGEN, Inc., Board of Regents, The University of Texas System
    Inventors: Willem W. Overwijk, Manisha Singh, Patrick Hwu, Mark Cantwell
  • Publication number: 20220409663
    Abstract: Embodiments of the disclosure provide methods and compositions that facilitate cancer treatment including at least because they concern therapies that circumvent the tumor microenvironment. In specific embodiments, compositions are utilized for therapy that utilize tumor-infiltrating lymphocytes and/or engineered T cells that are protected from immunosuppression from the tumor microenvironment because they are engineered to have reduced or eliminated expression of transforming growth factor-beta receptor 2 and/or I-cell-Ig-and-ITIM-domain and/or CD7 genes.
    Type: Application
    Filed: November 25, 2020
    Publication date: December 29, 2022
    Inventors: Samantha Marie FIX, Katy REZVANI, Patrick HWU, Simone PUNT, Soraya Zorro MANRIQUE
  • Publication number: 20210205293
    Abstract: The present disclosure relates to compositions and methods for treating cancer, more specifically to methods and compositions comprising a Topoisomerase I inhibitor and an ?-PD-L1 antibody
    Type: Application
    Filed: December 8, 2020
    Publication date: July 8, 2021
    Inventors: Patrick HWU, Jodi A. MCKENZIE, Rina M. MBOFUNG, Rodabe AMARIA
  • Publication number: 20210170002
    Abstract: Provided are SLC45A2 peptides that bind to MHC I (HLA-A2) on melanoma cells or other antigen-presenting cells and are recognized by T-cell receptors on T cells. The SLC45A2 peptides may be therapeutically used to treat a cancer, such as a cutaneous melanoma, uveal melanoma, a mucosal melanoma, or a metastatic melanoma. Methods for expanding a population of T cells that target SLC45A2 are also provided.
    Type: Application
    Filed: November 6, 2020
    Publication date: June 10, 2021
    Inventors: Gregory Lizée, Cassian Yee, Patrick Hwu, Janos Roszik
  • Publication number: 20210172961
    Abstract: The present disclosure relates to methods of identifying RNA-edited peptides. In an aspect, the identified peptides are capable of eliciting immune responses in individuals or patients. The present disclosure further relates to RNA-edited peptide sequences identified by methods described herein. In a further aspect, the disclosure provides for methods of treating cancer in individuals or patients by utilizing the methodology described herein.
    Type: Application
    Filed: July 26, 2019
    Publication date: June 10, 2021
    Inventors: Minying ZHANG, Jens FRITSCHE, Patrick HWU
  • Patent number: 10894044
    Abstract: The present disclosure relates to compositions and methods for treating cancer, more specifically to methods and compositions comprising a Topoisomerase I inhibitor and an ?-PD-L1 antibody.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: January 19, 2021
    Assignee: Board of Regents, The University of Texas System
    Inventors: Patrick Hwu, Jodi A. McKenzie, Rina M. Mbofung, Rodabe Amaria
  • Publication number: 20200353044
    Abstract: Provided herein are methods and compositions for treating cancer in an individual comprising administering to the individual an effective amount of a TLR agonist and a chimeric CD154 polypeptide. Also provided herein are methods of enhanced immune function.
    Type: Application
    Filed: April 11, 2018
    Publication date: November 12, 2020
    Applicant: MEMGEN, LLC
    Inventors: Willem OVERWIJK, Manisha SINGH, Patrick HWU, Mark CANTWELL
  • Publication number: 20200165339
    Abstract: Provided herein are methods and compositions for treating cancer in an individual comprising administering to the individual an effective amount of at least one immune checkpoint inhibitor and a chimeric CD 154 polypeptide. Also provided herein are methods of enhanced immune function.
    Type: Application
    Filed: November 2, 2016
    Publication date: May 28, 2020
    Applicants: Board of Regents, The University of Texas System, Memgen, LLC
    Inventors: Willem W. OVERWIJK, Manisha SINGH, Patrick HWU, Mark CANTWELL
  • Publication number: 20200115466
    Abstract: The present invention discloses a mouse-human chimeric antibody preferably recognizes the MUC1 glycopeptide epitope RPAPGS(GalNAc)TAPPAHG on the surface of cancer cells, and the encoding sequences, wherein the monoclonal antibody having a light chain and a heavy chain. Moreover, the present invention provides humanized light and heavy chains, and the encoding sequences. The results of paired expression show that humanized antibodies also recognize the MUC1 glycopeptide epitope RPAPGS(GalNAc)TAPPAHG on the surface of cancer cells, and show the same specificity as the parental antibody.
    Type: Application
    Filed: January 18, 2017
    Publication date: April 16, 2020
    Inventors: Dapeng ZHOU, Patrick HWU
  • Publication number: 20190275133
    Abstract: Provided herein are methods and compositions for treating a subject having cancer by administering to the subject a cancer vaccine accompanied by administration of a long acting IL-2R??-biased agonist.
    Type: Application
    Filed: November 9, 2017
    Publication date: September 12, 2019
    Inventors: Deborah H. Charych, Jonathan Zalevsky, Willem Overwijk, Meenu Sharma, Adi Diab, Patrick Hwu
  • Publication number: 20190169262
    Abstract: Provided are SLC45A2 peptides that bind to MHC I (HLA-A2) on melanoma cells or other antigen-presenting cells and are recognized by T-cell receptors on T cells. The SLC45 A2 peptides may be therapeutically used to treat a cancer, such as a cutaneous melanoma, uveal melanoma, a mucosal melanoma, or a metastatic melanoma. Methods for expanding a population of T cells that target SLC45A2 are also provided.
    Type: Application
    Filed: December 2, 2016
    Publication date: June 6, 2019
    Inventors: Gregory LIZÉE, Cassian YEE, Patrick HWU, Janos ROSZIK
  • Publication number: 20180263971
    Abstract: The present disclosure relates to compositions and methods for treating cancer, more specifically to methods and compositions comprising a Topoisomerase I inhibitor and an ?-PD-L1 antibody
    Type: Application
    Filed: September 16, 2016
    Publication date: September 20, 2018
    Inventors: Patrick HWU, Jodi A. MCKENZIE, Rina M. MBOFUNG, Rodabe AMARIA
  • Publication number: 20170363629
    Abstract: Provided herein are predictive biomarker signatures that identify patients as likely to benefit from TIL therapy. Also provided are tumor immunotherapy resistance pathways that may be targets of combination therapies to enhance TIL therapy.
    Type: Application
    Filed: November 5, 2015
    Publication date: December 21, 2017
    Inventors: Laszlo RADVANYI, Jie Qing CHEN, Patrick HWU
  • Patent number: 9512401
    Abstract: BTLA-positive (“BTLA+”) lymphocyte signaling drives T cells and kills tumors. BTLA functions as a positive modulator of anti-tumor (anti-melanoma) T cell responses, The BTLA+ T cell responds against tumor or cancer cells, and, in cancer patients respond better to IL-2 than BTLA-negative cells. Hence, the BTLA-positive T cell in cancers is a positive marker for selection of enriched anti-tumor-cancer reactive T cells and can be used or applied for adoptive T-cell therapy or for therapeutic purposes.
    Type: Grant
    Filed: September 30, 2011
    Date of Patent: December 6, 2016
    Assignee: Board of Regents, The University of Texas System
    Inventors: Laszlo Radvanyi, Patrick Hwu, Chantale Bernatchez
  • Publication number: 20130302300
    Abstract: BTLA-positive (“BTLA+”) lymphocyte signaling drives T cells and kills tumors. BTLA functions as a positive modulator of anti-tumor (anti-melanoma) T cell responses, The BTLA+ T cell responds against tumor or cancer cells, and, in cancer patients respond better to IL-2 than BTLA-negative cells. Hence, the BTLA-positive T cell in cancers is a positive marker for selection of enriched anti-tumor-cancer reactive T cells and can be used or applied for adoptive T-cell therapy or for therapeutic purposes.
    Type: Application
    Filed: September 30, 2011
    Publication date: November 14, 2013
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Laszlo Radvanyi, Patrick Hwu, Chantale Bernatchez